Search

Your search keyword '"Sadjadian P"' showing total 83 results
Start Over Author "Sadjadian P"
83 results on '"Sadjadian P"'

4. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Author

Pall, Georg, Surmont, Veerle, Bosquee, Léon, Germonpré, Paul, Brückl, Wolfgang, Grah, Christina, Herzmann, Christian, Leistner, Rumo, Meyer, Andreas, Müller, Lothar, Schmalz, Oliver, Scholz, Christian, Schröder, Michael, Serke, Monika, Wesseler, Claas, Brandts, Christian, Kopp, Hans-Georg, Blau, Wolfgang, Griesinger, Frank, Campelo, Maria Rosario Garcia, Garcia, Yolanda Garcia, Perez, José Manuel Trigo, Thomas, M., Ponce-Aix, S., Navarro, A., Riera-Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Dómine Gómez, M., Kollmeier, J., Sadjadian, P., Fröhling, K -P, Huber, R.M., and Wolf, M.

Published
2018
Full Text
View/download PDF

7. P1.15-05 Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)

Author

Reck, M., primary, Sadjadian, P., additional, Waller, C., additional, Kambartel, K., additional, Grohe, C., additional, Rittmeyer, A., additional, Sendler, A., additional, Reinmuth, N., additional, Keller, R., additional, von Suchodoletz, H., additional, Maenz, M., additional, and Sebastian, M., additional

Published
2022
Full Text
View/download PDF

9. 1348P First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN

Author

Kuon, J.B., Von der Heyde, E., Sadjadian, P., Bischoff, M., Hassler, A., Althoff, A., Wilop, S., Behringer, D.M., Blau, W., Hübner, G., Flieger, D., Ziske, C., Groschek, M., Laack, H-E., Mueller-Huesmann, H., Schumann, C., Waldenberger, D., and Gütz, S.

Published
2024
Full Text
View/download PDF

10. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Author

De Stefano, Valerio, Carobbio, Alessandra, Di Lazzaro, Vincenzo, Guglielmelli, Paola, Iurlo, Alessandra, Finazzi, Maria Chiara, Rumi, Elisa, Cervantes, Francisco, Elli, Elena Maria, Randi, Maria Luigia, Griesshammer, Martin, Palandri, Francesca, Bonifacio, Massimiliano, Hernandez-Boluda, Juan-Carlos, Cacciola, Rossella, Miroslava, Palova, Carli, Giuseppe, Beggiato, Eloise, Ellis, Martin H., Musolino, Caterina, Gaidano, Gianluca, Rapezzi, Davide, Tieghi, Alessia, Lunghi, Francesca, Loscocco, Giuseppe Gaetano, Cattaneo, Daniele, Cortelezzi, Agostino, Betti, Silvia, Rossi, Elena, Finazzi, Guido, Censori, Bruno, Cazzola, Mario, Bellini, Marta, Arellano-Rodrigo, Eduardo, Bertozzi, Irene, Sadjadian, Parvis, Vianelli, Nicola, Scaffidi, Luigi, Gomez, Montse, Cacciola, Emma, Vannucchi, Alessandro M., and Barbui, Tiziano

Published
2018
Full Text
View/download PDF

13. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Author

Verstovsek, Srdan, Gerds, Aaron T, Vannucchi, Alessandro M, Al-Ali, Haifa Kathrin, Lavie, David, Kuykendall, Andrew T, Grosicki, Sebastian, Iurlo, Alessandra, Goh, Yeow Tee, Lazaroiu, Mihaela C, Egyed, Miklos, Fox, Maria Laura, McLornan, Donal, Perkins, Andrew, Yoon, Sung-Soo, Gupta, Vikas, Kiladjian, Jean-Jacques, Granacher, Nikki, Lee, Sung-Eun, Ocroteala, Luminita, Passamonti, Francesco, Harrison, Claire N, Klencke, Barbara J, Ro, Sunhee, Donahue, Rafe, Kawashima, Jun, Mesa, Ruben, Abulafia, Adi Shacham, Al-Ali, Haifa Kathrin, Andreasson, Bjorn, Angona, Anna, Ayala, Rosa, Bang, Soo-Mee, Bank, Bruce, Barraco, Fiorenza, Beggiato, Eloise, Benghiat, Fleur Samantha, Bonifacio, MassimiliaNo, Bories, Claire, Borsaru, Gabriela, Brabrand, Mette, Braester, Andrei, Broliden, Andes, Buxhofer-Ausch, Veronika, Cambier, Nathalie, Caramella, Marianna, Carpentier, Benjamin, Cascavilla, Nicola, Castellano, Maria Giraldo, Chang, Hung, Chen, Chih-Cheng, Cheong, June-Won, Choi, Yunsuk, Choi, Philip, Corsetti, Maria Teresa, Cuadrado, Isabel Montero, Cunningham, Julia, Damaj, Gandhi Laurent, De Stefano, Valerio, Delage, Robert, Delgado, Regina Garcĺa, Diaz, Jose Miguel Torregrosa, Dombi, Péter, Dubruille, Viviane, Egyed, Miklós, El Fassi, Daniel, Elinder-Camburn, Anna, Elli, Elena Maria, Ellis, Martin, Fava, Carmen, Fazal, Salman, Fleischman, Angela, Foltz, Lynda, Fox, Laura, Gabrail, Nashat, Garcĺa-Gutiérrez, Jose Valentĺn, Gerds, Aaron, Girault, Stephane, Gisslinger, Heinz, Gluvacov, Alexandru, Goh, Yeow Tee, Göthert, Joachim, Granacher, Nikki, Grosicki, Sebastian, Gupta, Vikas, Hadjiev (Hadzhiev), Evgeni (Evgueniy), Hafraoui, Kaoutar, Hamed, Aryan, Harrison, Claire, Hasselbalch, Hans, Hauser, Hanns, Heaney, Mark, Hebart, Holger, Hernandez Rivas, Jesus Maria, Higuero Saavedra, Victor, Hillis, Christopher, Hou, Hsin-An, How, Jonathan, Huang, Daniel, Hus, Marek, Illés, Arpad, Isidori, Alessandro, Iurlo, Alessandra, Ivanov, Vadim, Johansson, Peter, Jung, Chul Won, Kiladjian, Jean-Jacques, Kirgner, Ilya, Koren-Michowitz, Maya, Koschmieder, Steffen, Kosztolanyi, Szabolcs Ors, Kreiniz, Natalia, Kuykendall, Andrew, Lambert, Jonathan, Laribi, Kamel, Lascaux, Axelle, Lavie, Noa, Lavie, David, Lazaroiu, Mihaela, Leahy, Michael, Lech-Maranda, Ewa, Lee, Sung-Eun, Lee, Won Sik, Legrand, Ollivier, Lemoli, Roberto, Liang, James, Lim, Sung-Nam, Loschi, Michael, Lucchesi, Alessandro, Macarie, Ioan, Marolleau, Jean-Pierre, Martelli, Maurizio, Mayer, Jiri, McCloskey, James, McDermott, Christopher, McLornan, Donal, McMahon, Brandon, Mehta, Priyanka, Mesa, Ruben, Mikala, Gábor, Milojkovic, Dragana, Mineur, Philippe, Mishchenko, Elena, Moon, Joon Ho, Nagy, Zsolt, Narayanan, Srinivasan, O'Connell, Casey, Ocroteala, Luminita, Oh, Stephen, Ojeda-Uribe, Mario, Ong, Kiat Hoe, Otegbeye, Folashade, Palmer, Jeanne, Pane, Fabrizio, Passamonti, Francesco, Patriarca, Andrea, Perkins, Andrew, Pietrantuono, Giuseppe, Plander, Mark, Platzbecker, Uwe, Prasad, Ritam, Prejzner, Witold, Rachow, Tobias, Radinoff, Atanas, Rejtő, László, Rinaldi, Ciro, Robak, Tadeusz, Rodriguez, Maria Angeles Fernandez, Ronson, Aaron, Ross, David, Sacha, Tomasz, Sadjadian, Parvis, Salar, Antonio, Santillana, Guillermo Sanz, Scheid, Christof, Schmidt, Aline, Severinsen, Marianne Tang, Stoeva, Vera, Szwedyk, Paweł, Tiribelli, Mario, Trautmann-Grill, Karolin, Trottier, Amy, Tzvetkov, Nikolay, van Droogenbroeck, Janusz, Vannucchi, Alessandro, Verstovsek, Srdan, Vianelli, Nicola, von Bubnoff, Nikolas, Wolf, Dominik, Woszczyk, Dariusz, Woźny, Tomasz, Wróbel, Tomasz, Xicoy, Blanca, Yeh, Su-Peng, and Yoon, Sung-Soo

Abstract

Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.

Published
2023
Full Text
View/download PDF

14. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Author

Sobas, Marta, Kiladjian, Jean-Jacques, Beauverd, Yan, Curto-Garcia, Natalia, Sadjadian, Parvis, Shih, Lee Yung, Devos, Timothy, Krochmalczyk, Dorota, Galli, Serena, Bieniaszewska, Maria, Seferynska, Ilona, McMullin, Mary Frances, Armatys, Anna, Spalek, Adrianna, Waclaw, Joanna, Zdrenghea, Mihnea, Legros, Laurence, Girodon, François, Lewandowski, Krzysztof, Angona Figueras, Anna, Samuelsson, Jan, Abuin Blanco, Aitor, Cony-Makhoul, Pascale, Collins, Angela, James, Chloé, Kusec, Rajko, Lauermannova, Marie, Noya, Maria Sol, Skowronek, Malgorzata, Szukalski, Lukasz, Szmigielska-Kaplon, Anna, Wondergem, Marielle, Dudchenko, Iryna, Gora Tybor, Joanna, Laribi, Kamel, Kulikowska de Nalecz, Anna, Demory, Jean-Loup, Le Du, Katell, Zweegman, Sonja, Besses Raebel, Carlos, Skoda, Radek, Giraudier, Stéphane, Griesshammer, Martin, Harrison, Claire N., and Ianotto, Jean-Christophe

Abstract

Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers in 15 countries. Sequential patients were included. We identified 444 patients, with median follow-up 9.7 years (0-47.8). Forty-nine (11.1%) had a history of thrombosis at diagnosis, 49 new thrombotic events were recorded (1.16% patient per year [pt/y]), perihepatic vein thromboses were most frequent (47.6% venous events), and logistic regression identified JAK2V617F mutation (P= .016) and hyperviscosity symptoms (visual disturbances, dizziness, vertigo, headache) as risk factors (P= .040). New hemorrhagic events occurred in 44 patients (9.9%, 1.04% pt/y). Disease transformation occurred in 48 patients (10.9%, 1.13% pt/y), usually to myelofibrosis (7.5%) with splenomegaly as a novel risk factor for transformation in essential thrombocythemia (ET) (P= .000) in logistical regression. Eight deaths (1.8%) were recorded, 3 after allogeneic stem cell transplantation. Concerning conventional risk scores: International Prognostic Score for Essential Thrombocythemia-Thrombosis and new International Prognostic Score for Essential Thrombocythemia-Thrombosis differentiated ET patients in terms of thrombotic risk. Both scores identified high-risk patients with the same median thrombosis-free survival of 28.5 years. No contemporary scores were able to predict survival for young ET or polycythemia vera patients. Our data represents the largest real-world study of MPN patients age < 25 years at diagnosis. Rates of thrombotic events and transformation were higher than expected compared with the previous literature. Our study provides new and reliable information as a basis for prospective studies, trials, and development of harmonized international guidelines for the specific management of young patients with MPN.

Published
2022
Full Text
View/download PDF

15. Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Author

Griesinger, F, additional, Eberhardt, WEE, additional, Bruch, HR, additional, Rauh, J, additional, von der Heyde, E, additional, Marschner, N, additional, Jaenicke, M, additional, Fleitz, A, additional, Spring, L, additional, Sahlmann, J, additional, Karatas, A, additional, Hipper, A, additional, Weichert, W, additional, Sadjadian, P, additional, Metzenmacher, M, additional, Gleiber, W, additional, Sebastian, M, additional, and Thomas, M, additional

Published
2020
Full Text
View/download PDF

16. Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Author

Griesinger, F., primary, Eberhardt, W.E.E., additional, Bruch, H.-R., additional, Rauh, J., additional, von der Heyde, E., additional, Marschner, N.W., additional, Jänicke, M., additional, Fleitz, A., additional, Spring, L., additional, Sahlmann, J., additional, Karatas, A., additional, Hipper, A., additional, Weichert, W., additional, Sadjadian, P., additional, Metzenmacher, M., additional, Gleiber, W., additional, Sebastian, M., additional, and Thomas, M., additional

Published
2019
Full Text
View/download PDF

18. A review of hydroxyurea-related cutaneous adverse events

Author

Griesshammer, Martin, Wille, Kai, Sadjadian, Parvis, Stegelmann, Frank, and Döhner, Konstanze

Abstract

ABSTRACTIntroduction: Hydroxyurea (HU) is an S-phase specific oral chemotherapeutic agent that inhibits ribonucleotide diphosphate reductase. It is the most common used cytoreductive drug in patients (pts) with BCR-ABL1negative myeloproliferative neoplasms (MPN) and sickle cell disease (SCD). The World Health Organization lists HU as an „essential drug“. Although most patients tolerate HU well, cutaneous adverse events (CAE) are frequent side effects and may limit its long-term use. This has become increasingly evident in recent years, especially in MPN patients, where CAE were previously underestimated and underdiagnosed.Areas covered: In this review, we present the available literature on HU-related CAE in MPN patients. In particular, data from a recently published and so far, only prospective non-interventional study investigating CAE in 172 MPN patients will be discussed in detail and compared with previously available data. Finally, we give an overview of the management of HU-related CAE in MPN patients and provide recommendations on the practical clinical approach.Expert opinion: In clinical practice, HU associated CAE are common and have important diagnostic and therapeutic consequences. Therefore, they should be considered in all MPN patients treated with HU in the future.

Published
2021
Full Text
View/download PDF

19. Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

Author

Thomas, M., primary, Ponce Aix, S., additional, Navarro Mendivil, A., additional, Riera Knorrenschild, J., additional, Schmidt, M., additional, Wiegert, E., additional, Kapp, K., additional, Mauri, C., additional, Domine Gomez, M., additional, Kollmeier, J., additional, Sadjadian, P., additional, Fröhling, K.-P., additional, Huber, R.M., additional, and Wolf, M., additional

Published
2018
Full Text
View/download PDF

20. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Author

Thomas, M., primary, Ponce-Aix, S., additional, Navarro, A., additional, Riera-Knorrenschild, J., additional, Schmidt, M., additional, Wiegert, E., additional, Kapp, K., additional, Wittig, B., additional, Mauri, C., additional, Dómine Gómez, M., additional, Kollmeier, J., additional, Sadjadian, P., additional, Fröhling, K -P, additional, Huber, R.M., additional, Wolf, M., additional, Pall, Georg, additional, Surmont, Veerle, additional, Bosquee, Léon, additional, Germonpré, Paul, additional, Brückl, Wolfgang, additional, Grah, Christina, additional, Herzmann, Christian, additional, Leistner, Rumo, additional, Meyer, Andreas, additional, Müller, Lothar, additional, Schmalz, Oliver, additional, Scholz, Christian, additional, Schröder, Michael, additional, Serke, Monika, additional, Wesseler, Claas, additional, Brandts, Christian, additional, Kopp, Hans-Georg, additional, Blau, Wolfgang, additional, Griesinger, Frank, additional, Campelo, Maria Rosario Garcia, additional, Garcia, Yolanda Garcia, additional, and Perez, José Manuel Trigo, additional

Published
2018
Full Text
View/download PDF

21. Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod

Author

Thomas, M., primary, Ponce-Aix, S., additional, Navarro Mendivil, A., additional, Riera Knorrenschild, J., additional, Schmidt, M., additional, Krikow, M., additional, Wiegert, E., additional, Domine Gomez, M., additional, Kollmeier, J., additional, Sadjadian, P., additional, Fröhling, K.P., additional, Huber, R.M., additional, and Wolf, M., additional

Published
2017
Full Text
View/download PDF

23. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Author

Griesinger, Frank, Sebastian, Martin, Brueckl, Wolfgang M., Hummel, Horst-Dieter, Jaeschke, Bastian, Kern, Jens, Wesseler, Claas, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Hipper, Annette, Groth, Annika, Weichert, Wilko, Dörfel, Steffen, Petersen, Volker, Schröder, Jan, Wilke, Jochen, Eberhardt, Wilfried E.E., Thomas, Michael, Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, de Wit, Maike, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Eberhardt, Wilfried, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Griesinger, Frank, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig Carla, Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hummel, Horst-Dieter, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kaiser, Ulrich, Kamal, Haytham, Kambartel, Kato, Kern, Jens, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Müller, Lothar, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schäfer, Harald, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt Peter, Florian, Sebastian, Martin, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Uhlig, Jens, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, and Zeth, Matthias

Abstract

Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of “trial-ineligible” and “potentially trial-eligible” patients.

Published
2024
Full Text
View/download PDF

24. 1500P - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Author

Griesinger, F., Eberhardt, W.E.E., Bruch, H.-R., Rauh, J., von der Heyde, E., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Sadjadian, P., Metzenmacher, M., Gleiber, W., Sebastian, M., and Thomas, M.

Published
2019
Full Text
View/download PDF

27. Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Author

Stegelmann, Frank, Wille, Kai, Busen, Hannah, Fuchs, Christiane, Schauer, Stefanie, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Döhner, Hartmut, Stadler, Rudolf, Döhner, Konstanze, and Griesshammer, Martin

Published
2024
Full Text
View/download PDF

30. Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer (Nsclc) with Imprime Pgg (Ipgg) in Combination with Cetuximab, Carboplatin and Paclitaxel–Analysis of Secondary Endpoints of a Multicenter, Randomized Phase 2 Trial

Author

Schneller, F., primary, Thomas, M., additional, Sadjadian, P., additional, Kollmeier, J., additional, Bose, N., additional, Patchen, M.L., additional, Lowe, J., additional, Mattson, P., additional, Gargano, M., additional, Huhn, R.D., additional, and Braun, A., additional

Published
2014
Full Text
View/download PDF

31. Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Author

Beauverd, Yan, Ianotto, Jean-Christophe, Thaw, Kyaw Htin, Sobas, Marta, Sadjadian, Parvis, Curto-Garcia, Natalia, Shih, Lee-Yung, Devos, Timothy, Krochmalczyk, Dorota, Galli, Serena, Bieniaszewska, Maria, Seferynska, Ilona, McMullin, Mary Frances, Armatys, Anna, Spalek, Adrianna, Waclaw, Joanna, Zdrenghea, Mihnea Tudor, Legros, Laurence, Girodon, Francois, Lewandowski, Krzysztof, Angona Figueras, Anna, Samuelsson, Jan, Abuin Blanco, Aitor, Cony-Makhoul, Pascale, Collins, Angela, James, Chloe, Kusec, Rajko, Lauermannova, Marie, Noya, Maria Soledad, Skowronek, Malgorzata, Szukalski, Lukasz, Szmigielska-Kaplon, Anna, Wondergem, Marielle, Dudchenko, Iryna, Gora-Tybor, Joanna, Laribi, Kamel, Kulikowska De Nalecz, Anna, Demory, Jean-Loup, Le Du, Katell, Zweegman, Sonja, Besses Raebel, Carlos, Skoda, Radek C., Giraudier, Stephane, Griesshammer, Martin, Kiladjian, Jean-Jacques, and Harrison, Claire N

Abstract

Introduction

Published
2023
Full Text
View/download PDF

33. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium

Author

Griesshammer, Martin and Sadjadian, Parvis

Abstract

ABSTRACTIntroduction: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET). They are characterized by stem cell-derived clonal proliferation, harbor Janus kinase 2 (JAK2), or calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) driver mutations and exert an over activated JAK-signal transducer and activator of transcription (STAT) pathway. Therefore JAK inhibiting strategies have been successfully investigated in MPN clinical trials.Areas covered: The present review aims to provide a concise overview of the current and future role of JAK inhibitors in the therapeutic armamentarium of MPN.Expert opinion: The JAK1/JAK2 inhibitor ruxolitinib has clearly enriched the therapeutic armamentarium of MPN and is now licenced for more than five years in MF and over three years as second line in PV. Momelotinib, although of limited activity in MPN trials, demonstrated unique property of improving MF associated anemia. Less myelosuppressive or more selective JAK inhibitors like pacritinib, NS-01872 or Itacitinib are new promising agents tested in MF. JAK inhibition has become a cornerstone of MPN therapy and future efforts focus on ruxolitinib-based combinations and new JAK inhibitors.

Published
2017
Full Text
View/download PDF

37. Validation of a Self- directed Learning Readiness Scale for Medical and Dentistry Students.

Author

Nadi, Mohammad Ali and Sadjadian, Ilnaz

Subjects
CONTROL (Psychology), ADULT learning, DENTAL students, FACTOR analysis, MEDICAL students, MOTIVATION (Psychology), RESEARCH evaluation, STATISTICS, DATA analysis, CROSS-sectional method, RESEARCH methodology evaluation, DATA analysis software
Abstract

Introduction: Faculty members, being in charge of cultivating students' life-long learning capabilities, need a valid and reliable tool to assess self-directed learning readiness among them. The aim of this study was to examine assess reliability and construct validity of the Self Directed Learning Readiness Scale (SDLRS) for pre-internship medical and dentistry students. Methods: In a cross-sectional psychometric study, 335 pre-internship medical and dentistry students, studying in Islamic Azad University- Khurasgan and Najaf Abad branches, took the survey in 2008. The subjects completed Fisher's Self-Directed Learning Readiness Scale(SDLRS). The scale has 40 items in 3 subscales. Data were analyzed through using Spearman Brown correlation coefficient and confirmatory factor analysis by LISREL software. Results: The resulting SDLRS consisted of 40 items across the following three domains: Self-management, desire to learning, and self-control. The final model in confirmatory factor analysis revealed that 39 items indicated a good fit of model. The value of Cronbach's Alpha showed that all of 3 factors have high internal consistency coefficients. Conclusion: This scale is a valid and reliable instrument in assessing students' readiness for self directed learning. [ABSTRACT FROM AUTHOR]

Published
2011

38. Design and implementation of an optimal multiple-model adaptive controller for line-of-sight stabilization

Author

Jalali, Ali, Golmohammad, Hassan, and Sadjadian, Houman

Abstract

Vibration reduces the ability of a camera to detect far-away targets that lead to the use of stabilized platforms. Despite much research on stabilized platforms, the need for more accurate systems still exists as a consequence of sensor resolution improvements. In this article, a multiple-model adaptive controller is designed for a single-axis system. There are two important problems associated with multiple-model controllers: number of models and their locations in an operating space. After describing the problem, the stability of the control scheme is verified in theory. Next, the closed-loop stability condition is used to find the minimum number of models. After that, models are located in a space of an unknown parameter by defining a cost function for line-of-sight stabilization. The performance of the introduced multiple-model controller is evaluated in simulation and real-time implementation. Then it is compared with a proportional-plus-integral controller and an H∞-optimal controller. As a result, the stability accuracy of the test platform improves in both simulation and real-time implementation.

Published
2013
Full Text
View/download PDF

39. A Comprehensive Mechatronic Modeling and Simulation of Electric Power Steering System

Author

Rezaei, Hamed and Sadjadian, Houman

Abstract

Electric power steering (EPS) systems are rapidly replacing existing traditional hydraulic power steering systems due to their important advantages such as fuel and cost savings, environmental compatibility and flexibility. Many articles are available in this field in which EPS is viewed only from one specific aspect. Other aspects have been introduced only by brief equations neglecting some main details regarding the important effects of ignored parts. Therefore, it is quite necessary to make a complete analysis of every part of this system with a right combination between them. It makes a comprehensive simulation system for EPS. This matter needs sufficient knowledge in mechanical, electrical and control sciences and how to assemble them with each other properly. Therefore, Mechatronic is the most appropriate branch of science to achieve this goal. In this paper, a complete model of EPS is presented which includes a 7-D.O.F mechanical model of steering system. A Permanent Magnet Synchronous Machine (PMSM) is used to supply the assist torque to steering column. Vector Control Method is utilized for controlling the motor. A PID controller determines the reference assist torque value. The results are presented to estimate the model precision and evaluation of model.

Published
2011
Full Text
View/download PDF

40. Non-linear power system robust stabiliser based on sliding mode technique

Author

Mohammadian, Mohsen and Sadjadian, Houman

Abstract

This paper presents a new method for designing non-linear power system stabiliser to improve transient and dynamic stability. In these studies, a 4th order non-linear model of synchronous generator has been used. First, the existence of a diffeomorphism transformation for non-linear power system has been proved and then, the non-linear model has been transformed to a canonical form using input-output linearisation method. Finally, the linearised model is controlled using sliding mode technique. At these procedures, the stability of zero dynamics has been attained. The simulation results on a single machine connected to an infinite bus confirm the feasibility and show the good performance of the stabiliser.

Published
2010

43. Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Author

Jean-Christophe, Ianotto, Kiladjian, Jean-Jacques, Sobas, Marta, Sadjadian, Parvis, Shih, Lee-Yung, Bieniaszewska, Maria, Seferynska, Ilona, McMullin, Mary Frances, Waclaw, Joanna, Legros, Laurence, Lewandowski, Krzysztof, Zdrenghea, Mihnea, Abuin Blanco, Aitor, Armatys, Anna, Samuelsson, Jan, Spalek, Adrianna, Angola Figueras, Anna, Lauermannova, Marie, Noya, María-Soledad, Czyz, Jaroslaw, Szmigielska-Kaplon, Anna, Kusec, Rajko, Gora Tybor, Joanna, Masternak, Anna, Michiels, Jan J., Skowronek, Malgorzata, Demory, Jean-Loup, Le Du, Katell, Zweegman, Sonja, Besses Raebel, Carlos, Giraudier, Stephane, Griesshammer, Martin, and Harrison, Claire N.

Abstract

Kiladjian: Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; AOP Orphan: Membership on an entity's Board of Directors or advisory committees, Research Funding. Giraudier:Novartis: Research Funding. Griesshammer:Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Harrison:Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria; Gilead: Honoraria, Speakers Bureau; CTI BioPharma: Consultancy, Honoraria.

Published
2018
Full Text
View/download PDF

44. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Author

Barbui, Tiziano, De Stefano, Valerio, Carobbio, Alessandra, Di Lazzaro, Vincenzo, Guglielmelli, Paola, Loscocco, Giuseppe Gaetano, Iurlo, Alessandra, Cattaneo, Daniele, Cortelezzi, Agostino, Betti, Silvia, Rossi, Elena, Finazzi, Maria Chiara, Finazzi, Guido, Censori, Bruno, Cazzola, Mario, Rumi, Elisa, Bellini, Marta, Cervantes, Francisco, Arellano-Rodrigo, Eduardo, Elli, Elena, Randi, Maria Luigia, Bertozzi, Irene, Griesshammer, Martin, Sadjadian, Parvis, Palandri, Francesca, Vianelli, Nicola, Bonifacio, Massimiliano, Scaffidi, Luigi, Hernandez-Boluda, Juan Carlos, Gomez, Montse, Cacciola, Emma, Cacciola, Rossella Rosari, Miroslava, Palova, Carli, Giuseppe, Beggiato, Eloise, Ellis, Martin H, Musolino, Caterina, Gaidano, Gianluca, Rapezzi, Davide, Tieghi, Alessia, Lunghi, Francesca, and Vannucchi, Alessandro M.

Abstract

BACKGROUND.Very few previous studies have estimated the risk of recurrence after cerebral transient ischemic attack (TIA) or ischemic stroke (IS) in patients with myeloproliferative neoplasms (MPN). PRISM (Preventing Ischemic Stroke in Myeloproliferative Neoplasms) is an international investigator-driven study with three purposes: (1) to describe the clinical profile at presentation of ischemic TIA/IS in contemporary patients with polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF); (2) to evaluate the short and long-term outcomes beyond the acute phase and to explore their comparability with non MPN population; (3) to refine the risk assessment for recurrences and cardiovascular mortality.

Published
2017
Full Text
View/download PDF

46. Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Author

Wille K, Dumke M, Wilsdorf N, Sadjadian P, Schneider A, Jender-Bartling S, Kolatzki V, Horstmann A, Meixner R, Jiménez-Muñoz M, Fuchs C, Tischler HJ, and Griesshammer M

Subjects
Humans, Male, Female, Middle Aged, Aged, Adult, Retrospective Studies, Idarubicin administration & dosage, Vidarabine analogs & derivatives, Vidarabine administration & dosage, Vidarabine therapeutic use, Treatment Outcome, Recurrence, Salvage Therapy, Drug Resistance, Neoplasm, Prognosis, Aged, 80 and over, Granulocyte Colony-Stimulating Factor, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute diagnosis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cytarabine administration & dosage, Cytarabine therapeutic use
Abstract

Introduction: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes., Patients and Methods: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy., Results: Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log-rank-test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group., Conclusions: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy., (© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)

Published
2025
Full Text
View/download PDF

47. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET.

Author

Wille K, Brouka M, Bernhardt J, Rüfer A, Niculescu-Mizil E, Gotic M, Isfort S, Koschmieder S, Barbui T, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Stegelmann F, Döhner K, Kiladjian JJ, and Griesshammer M

Abstract

Competing Interests: KW and MG declares funding, advisory board honoraria and other financial support (eg, travel support) from Amgen, AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Lilly. SI declares honoraria from Pfizer, AOP Orphan, Novartis, Incyte and Abbvie, advisory board honoraria from Pfizer, Novartis, GSK and Incyte and other financial support (travel support) from Pfizer, Novartis, AOP Orphan and Alexion. SK reports funding from Novartis, Bristol-Myers Squibb, Janssen/Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, and GSK; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, Sierra Oncology, Karthos, Imago Bioscience, and GSK; serves as an editor for HemaSphere; and other financial support (eg, travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Biosciences, and GSK. KD declares consulting/advisory role/honoraria from AbbVie, Celgene/BMS, Novartis, CTI BioPharma Corp, and Roche. J-JK declares consulting/advisory role/honoraria from AbbVie, BMS, Novartis, AOP Health. All the other authors have no conflicts of interest to disclose.

Published
2023
Full Text
View/download PDF

48. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.

Author

Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, and Griesshammer M

Subjects
Adolescent, Adult, Aged, Anticoagulants therapeutic use, Biomarkers, Biomarkers, Tumor, Biopsy, Blood Coagulation, Bone Marrow, Child, Disease Management, Disease Susceptibility, Female, Fusion Proteins, bcr-abl genetics, Hemorrhage diagnosis, Hemorrhage therapy, Humans, Incidence, Male, Middle Aged, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders genetics, Prognosis, Risk Assessment, Risk Factors, Survival Rate, Young Adult, Hemorrhage epidemiology, Hemorrhage etiology, Myeloproliferative Disorders complications, Myeloproliferative Disorders epidemiology
Abstract

In patients with bcr-abl-negative myeloproliferative neoplasms (MPN), concerns are often raised about the use of anticoagulants because of an increased bleeding risk. However, there are few MPN studies focusing on bleeding. To investigate bleeding complications in MPN, we report our retrospective, single-center study of 829 patients with a median follow-up of 5.5 years (range: 0.1-35.6). A first bleeding event occurred in 143 of 829 patients (17.2%), corresponding to an incidence rate of 2.29% per patient/year. During the follow-up period, one out of 829 patients (0.1%) died due to bleeding. Regarding anticoagulation, most bleeding occurred in patients on antiplatelet therapies (60.1%), followed by patients on anticoagulation therapies (20.3%) and patients not on anticoagulation (19.6%). In multivariate analysis, administration of antiplatelet (HR 2.31 [1.43, 3.71]) and anticoagulation therapies (HR 4.06 [2.32, 7.09]), but not age, gender or mutation status, was associated with an increased bleeding risk. Comparing the "probability of bleeding-free survival" between the MPN subtypes, no significant difference was observed (p = 0.91, log-rank test). Our retrospective study shows that antiplatelet and anticoagulation therapies significantly increase the risk of bleeding in MPN patients without affecting mortality. However, there is no reason to refrain from guideline-conform primary or secondary anticoagulation in MPN patients., (© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

50. The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera.

Author

Wille K, Bernhardt J, Sadjadian P, Becker T, Kolatzki V, Huenerbein K, and Griesshammer M

Subjects
Abortion, Spontaneous, Adolescent, Adult, Female, Heparin, Low-Molecular-Weight, Humans, Polycythemia Vera complications, Pregnancy, Pregnancy Outcome, Retrospective Studies, Thrombocythemia, Essential therapy, Treatment Outcome, Young Adult, Hemorrhage etiology, Polycythemia Vera physiopathology, Polycythemia Vera therapy, Pregnancy Complications physiopathology, Pregnancy Complications therapy
Abstract

Objectives: Pregnancies in women with polycythemia vera (PV) are associated with an increased risk of PV-related maternal complications and often result in miscarriage. Recommendations for the management of PV pregnancies are mainly based on studies with a small number of patients. A correlation between pregnancy outcome and postpartum course has been reported for essential thrombocythemia, but corresponding data for PV are lacking so far., Methods: In 41 PV pregnancies, the pregnancy outcome, the use of PV-specific therapies (ie, acetylsalicylic acid, low-molecular weight heparin and/or interferon-alpha), and the postpartum PV course were investigated., Results: A live birth rate of 51.2% (21/41 pregnancies) was observed. 43.9% of pregnancies ended in spontaneous abortion and 4.9% in stillbirth. A significantly increased live birth rate occurred in pregnancies with PV-specific therapies compared to standard antenatal care (69.0% vs. 8.3%; P < .0019). The use of PV-specific therapy significantly increased the number of maternal hemorrhages (P = .021) without increasing the risk of fetal complications. During the median postpartum follow-up period of 1.2 years (range 0.1-13.7), complicated postpartum PV occurred significantly more often after miscarriages (P = .035)., Conclusions: According to our analysis, PV-specific therapy improved the live birth rate. Significantly more complicated postpartum PV courses were observed after miscarriages., (© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results